|
1
|
Carey LA, Dees EC, Sawyer L, et al: The
triple negative paradox: primary tumor chemosensitivity of breast
cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dent R, Trudeau M, Pritchard KI, et al:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tischkowitz M, Brunet JS, Bégin LR, et al:
Use of immunohistochemical markers can refine prognosis in triple
negative breast cancer. BMC Cancer. 7:1342007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schally AV, Steelman SL and Bowers CY:
Effect of hypothalamic extracts on release of growth hormone in
vitro. Proc Soc Exp Biol Med. 119:208–212. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rick FG, Schally AV, Block NL, et al:
Antagonists of growth hormone-releasing hormone (GHRH) reduce
prostate size in experimental benign prostatic hyperplasia. Proc
Natl Acad Sci USA. 108:3755–3760. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kiaris H, Chatzistamou I, Papavassiliou AG
and Schally AV: Growth hormone-releasing hormone: not only a
neurohormone. Trends Endocrinol Metab. 22:311–317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rick FG, Szalontay L, Schally AV, et al:
Combining growth hormone-releasing hormone antagonist with
luteinizing hormone-releasing hormone antagonist greatly augments
benign prostatic hyperplasia shrinkage. J Urol. 187:1498–1504.
2012. View Article : Google Scholar
|
|
8
|
Bagnato A, Moretti C, Ohnishi J, Frajese G
and Catt KJ: Expression of the growth hormone-releasing hormone
gene and its peptide product in the rat ovary. Endocrinology.
130:1097–1102. 1992.PubMed/NCBI
|
|
9
|
Rick FG, Schally AV, Szalontay L, et al:
Antagonists of growth hormone-releasing hormone inhibit growth of
androgen-independent prostate cancer through inactivation of ERK
and Akt kinases. Proc Natl Acad Sci USA. 109:1655–1660. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Busto R, Schally AV, Braczkowski R, et al:
Expression of mRNA for growth hormone-releasing hormone and splice
variants of GHRH receptors in human malignant bone tumors. Regul
Pept. 108:47–53. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Busto R, Schally AV, Varga JL, et al: The
expression of growth hormone-releasing hormone (GHRH) and splice
variants of its receptor in human gastroenteropancreatic
carcinomas. Proc Natl Acad Sci USA. 99:11866–11871. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chatzistamou I, Schally AV, Kiaris H, et
al: Immunohisto-chemical detection of GHRH and its receptor splice
variant 1 in primary human breast cancers. Eur J Endocrinol.
151:391–396. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Engel JB, Keller G, Schally AV, et al:
Inhibition of growth of experimental human endometrial cancer by an
antagonist of growth hormone-releasing hormone. J Clin Endocrinol
Metab. 90:3614–3621. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Frohman LA and Szabo M: Ectopic production
of growth hormone-releasing factor by carcinoid and pancreatic
islet tumors associated with acromegaly. Prog Clin Biol Res.
74:259–271. 1981.PubMed/NCBI
|
|
15
|
Garcia-Fernandez MO, Schally AV, Varga JL,
Groot K and Busto R: The expression of growth hormone-releasing
hormone (GHRH) and its receptor splice variants in human breast
cancer lines; the evaluation of signaling mechanisms in the
stimulation of cell proliferation. Breast Cancer Res Treat.
77:15–26. 2003. View Article : Google Scholar
|
|
16
|
Guo J, Schally AV, Zarandi M, Varga J and
Leung PC: Antiproliferative effect of growth hormone-releasing
hormone (GHRH) antagonist on ovarian cancer cells through the
EGFR-Akt pathway. Reprod Biol Endocrinol. 8:542010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kahán Z, Arencibia JM, Csernus VJ, et al:
Expression of growth hormone-releasing hormone (GHRH) messenger
ribonucleic acid and the presence of biologically active GHRH in
human breast, endometrial, and ovarian cancers. J Clin Endocrinol
Metab. 84:582–589. 1999.PubMed/NCBI
|
|
18
|
Schally A and Varga JL: Antagonists of
growth hormone-releasing hormone. Comb Chem High Throughput Screen.
9:163–170. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schally AV, Comaru-Schally AM, Nagy A, et
al: Hypothalamic hormones and cancer. Front Neuroendocrinol.
22:248–291. 2001. View Article : Google Scholar
|
|
20
|
Schally AV, Varga JL and Engel JB:
Antagonists of growth-hormone-releasing hormone: an emerging new
therapy for cancer. Nat Clin Pract Endocrinol Metab. 4:33–43. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Barabutis N, Siejka A, Schally AV, Block
NL, Cai R and Varga L: Activation of mitogen-activated protein
kinases by a splice variant of GHRH receptor. J Mol Endocrinol.
44:127–134. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barabutis N, Tsellou E, Schally AV,
Kouloheri S, Kalofoutis A and Kiaris H: Stimulation of
proliferation of MCF-7 breast cancer cells by a transfected splice
variant of growth hormone-releasing hormone receptor. Proc Natl
Acad Sci USA. 104:5575–5579. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Havt A, Schally AV, Halmos G, et al: The
expression of the pituitary growth hormone-releasing hormone
receptor and its splice variants in normal and neoplastic human
tissues. Proc Natl Acad Sci USA. 102:17424–17429. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rekasi Z, Czompoly T, Schally AV and
Halmos G: Isolation and sequencing of cDNAs for splice variants of
growth hormone-releasing hormone receptors from human cancers. Proc
Natl Acad Sci USA. 97:10561–10566. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Köster F, Engel JB, Schally AV, et al:
Triple-negative breast cancers express receptors for growth
hormone-releasing hormone (GHRH) and respond to GHRH antagonists
with growth inhibition. Breast Cancer Res Treat. 116:273–279.
2009.PubMed/NCBI
|
|
26
|
Pombo CM, Zalvide J, Gaylinn BD and
Dieguez C: Growth hormone-releasing hormone stimulates
mitogen-activated protein kinase. Endocrinology. 141:2113–2119.
2000.PubMed/NCBI
|
|
27
|
Siriwardana G, Bradford A, Coy D and
Zeitler P: Autocrine/paracrine regulation of breast cancer cell
proliferation by growth hormone releasing hormone via Ras, Raf, and
mitogen-activated protein kinase. Mol Endocrinol. 20:2010–2019.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Berchem GJ, Bosseler M, Mine N and
Avalosse B: Nanomolar range docetaxel treatment sensitizes MCF-7
cells to chemotherapy induced apoptosis, induces G2M arrest and
phosphorylates bcl-2. Anticancer Res. 19:535–540. 1999.
|
|
29
|
Lavelle F, Bissery MC, Combeau C, Riou JF,
Vrignaud P and André S: Preclinical evaluation of docetaxel
(Taxotere). Semin Oncol. 22:3–16. 1995.
|
|
30
|
Buchholz S, Schally AV, Engel JB, et al:
Potentiation of mammary cancer inhibition by combination of
antagonists of growth hormone-releasing hormone with docetaxel.
Proc Natl Acad Sci USA. 104:1943–1946. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kovács M, Schally AV, Hohla F, et al: A
correlation of endocrine and anticancer effects of some antagonists
of GHRH. Peptides. 31:1839–1846. 2010.PubMed/NCBI
|
|
32
|
Rick FG, Schally AV, Block NL, et al: LHRH
antagonist Cetrorelix reduces prostate size and gene expression of
proinflammatory cytokines and growth factors in a rat model of
benign prostatic hyperplasia. Prostate. 71:736–747. 2011.
View Article : Google Scholar
|
|
33
|
Umemura S, Yoshida S, Ohta Y, Naito K,
Osamura RY and Tokuda Y: Increased phosphorylation of Akt in
triple-negative breast cancers. Cancer Sci. 98:1889–1892. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eralp Y, Derin D, Ozluk Y, et al: MAPK
overexpression is associated with anthracycline resistance and
increased risk for recurrence in patients with triple-negative
breast cancer. Ann Oncol. 19:669–674. 2008. View Article : Google Scholar : PubMed/NCBI
|
